Cargando…
Targeting the Src N-terminal regulatory element in cancer
The signaling pathways displayed by cancer cells are often composed by the same components than the physiological ones, yet the overall result is a pathological deregulation. The non-receptor protein tyrosine kinase Src is a good example. Src is the first described proto-oncogene and a demonstrated...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197966/ https://www.ncbi.nlm.nih.gov/pubmed/37204272 http://dx.doi.org/10.18632/oncotarget.28434 |
_version_ | 1785044651611258880 |
---|---|
author | Mezquita, Betlem Reyes-Farias, Marjorie Pons, Miquel |
author_facet | Mezquita, Betlem Reyes-Farias, Marjorie Pons, Miquel |
author_sort | Mezquita, Betlem |
collection | PubMed |
description | The signaling pathways displayed by cancer cells are often composed by the same components than the physiological ones, yet the overall result is a pathological deregulation. The non-receptor protein tyrosine kinase Src is a good example. Src is the first described proto-oncogene and a demonstrated player in cancer progression, as it affects proliferation, invasion, survival, cancer stemness, and drug resistance. Src activation is linked to poor prognosis in many cancer types, yet mutations in this protein are rarely observed. In addition, being a demonstrated cancer target, unspecific inhibition of the kinase activity has proven inefficient in clinics since the inhibition of Src in non-cancerous cells results in unacceptable toxicity. Thus, there is a need for new target regions in Src that could inhibit Src activity only in certain cell types, e.g., cancer cells, while maintaining the normal physiological activity in healthy cells. The Src N-terminal regulatory element (SNRE) includes the poorly studied intrinsically disordered region with unique sequences for each of the members of the Src family. In this perspective, we discuss the non-canonical regulatory mechanisms involving the SNRE and their potential use as oncotargets. |
format | Online Article Text |
id | pubmed-10197966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-101979662023-05-20 Targeting the Src N-terminal regulatory element in cancer Mezquita, Betlem Reyes-Farias, Marjorie Pons, Miquel Oncotarget Research Perspective The signaling pathways displayed by cancer cells are often composed by the same components than the physiological ones, yet the overall result is a pathological deregulation. The non-receptor protein tyrosine kinase Src is a good example. Src is the first described proto-oncogene and a demonstrated player in cancer progression, as it affects proliferation, invasion, survival, cancer stemness, and drug resistance. Src activation is linked to poor prognosis in many cancer types, yet mutations in this protein are rarely observed. In addition, being a demonstrated cancer target, unspecific inhibition of the kinase activity has proven inefficient in clinics since the inhibition of Src in non-cancerous cells results in unacceptable toxicity. Thus, there is a need for new target regions in Src that could inhibit Src activity only in certain cell types, e.g., cancer cells, while maintaining the normal physiological activity in healthy cells. The Src N-terminal regulatory element (SNRE) includes the poorly studied intrinsically disordered region with unique sequences for each of the members of the Src family. In this perspective, we discuss the non-canonical regulatory mechanisms involving the SNRE and their potential use as oncotargets. Impact Journals LLC 2023-05-19 /pmc/articles/PMC10197966/ /pubmed/37204272 http://dx.doi.org/10.18632/oncotarget.28434 Text en Copyright: © 2023 Mezquita et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Perspective Mezquita, Betlem Reyes-Farias, Marjorie Pons, Miquel Targeting the Src N-terminal regulatory element in cancer |
title | Targeting the Src N-terminal regulatory element in cancer |
title_full | Targeting the Src N-terminal regulatory element in cancer |
title_fullStr | Targeting the Src N-terminal regulatory element in cancer |
title_full_unstemmed | Targeting the Src N-terminal regulatory element in cancer |
title_short | Targeting the Src N-terminal regulatory element in cancer |
title_sort | targeting the src n-terminal regulatory element in cancer |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197966/ https://www.ncbi.nlm.nih.gov/pubmed/37204272 http://dx.doi.org/10.18632/oncotarget.28434 |
work_keys_str_mv | AT mezquitabetlem targetingthesrcnterminalregulatoryelementincancer AT reyesfariasmarjorie targetingthesrcnterminalregulatoryelementincancer AT ponsmiquel targetingthesrcnterminalregulatoryelementincancer |